Breaking News Instant updates and real-time market news.

RVNC

Revance

$20.60

0.1 (0.49%)

16:48
01/18/17
01/18
16:48
01/18/17
16:48

Revance to present RT002 data at January conference, says highlights efficacy

Revance Therapeutics announced presentations of clinical data for DaxibotulinumtoxinA Injectable, or RT002, at the TOXINS 2017 conference January 18-21. The presentations include final data from the Phase 2 BELMONT trial and interim results from a separate Phase 2 study of RT002 in isolated cervical dystonia. "These presentations highlight the safety, efficacy and duration-of-effect results for RT002 injectable from prior studies in both low and high dose indications. We are excited by the prospects of developing a next-generation neurotoxin with an improved safety profile, enhanced treatment effectiveness and long duration, whether for facial aesthetics, acute conditions or chronic disease states. We look forward to reporting results from four ongoing RT002 clinical trials in 2017, including the two SAKURA Phase 3 pivotal trials in glabellar lines, the final results for the Phase 2 trial in cervical dystonia and topline results from a Phase 2 trial for plantar fasciitis," remarked CEO Dan Browne.

RVNC Revance
$20.60

0.1 (0.49%)

06/14/16
RHCO
06/14/16
NO CHANGE
RHCO
Revance price target lowered to $22 from $46 at SunTrust
SunTrust cut its price target on Revance after the company discontinued its RT001 topical development program for lateral canthal lines and excessive sweating due to negative Ph-3 REALISE-1 data. The firm notes that the company is still working on a number of additional treatments. It keeps a Buy rating on the shares.
06/14/16
COWN
06/14/16
NO CHANGE
COWN
Outperform
Revance shares defended at Cowen
06/14/16
COWN
06/14/16
NO CHANGE
Target $55
COWN
Outperform
Revance key value driver remains RT002, says Cowen
Cowen analyst Ken Cacciatore said he shares in the disappointment that Revance's RT001 program is not moving forward, but adds that he believes expectations were low and that investor focus had already shifted, and remains fixed, on the injectable RT002 program, which is the company's key value driver. Cacciatore, who still thinks that RT002 could become a $1B+ product, maintains an Outperform rating and $55 price target on Revance shares, which are down 22% to $14.30 in morning trading.
11/29/16
AGIS
11/29/16
INITIATION
Target $28
AGIS
Buy
Revance initiated with a Buy at Aegis
Aegis analyst Difei Yang initiated Revance with a Buy and a $28 price target.

TODAY'S FREE FLY STORIES

TWTR

Twitter

$44.70

0.45 (1.02%)

06:15
07/18/18
07/18
06:15
07/18/18
06:15
Downgrade
Twitter rating change  »

Twitter downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

VSTM

Verastem

$8.10

-0.14 (-1.70%)

06:15
07/18/18
07/18
06:15
07/18/18
06:15
Conference/Events
Verastem management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 05

    Oct

GOOG

Alphabet

$1,198.81

14.57 (1.23%)

, GOOGL

Alphabet Class A

$1,213.65

17.07 (1.43%)

06:14
07/18/18
07/18
06:14
07/18/18
06:14
Periodicals
Nest CEO removed as unit brought under Google Home team, CNet reports »

Google has removed Marwan…

GOOG

Alphabet

$1,198.81

14.57 (1.23%)

GOOGL

Alphabet Class A

$1,213.65

17.07 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 08

    Aug

  • 18

    Sep

  • 28

    Oct

OPTN

Optinose

$26.61

(0.00%)

06:13
07/18/18
07/18
06:13
07/18/18
06:13
Recommendations
Optinose analyst commentary  »

Optinose price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGVT

Ingevity

$90.74

2.91 (3.31%)

06:12
07/18/18
07/18
06:12
07/18/18
06:12
Recommendations
Ingevity analyst commentary  »

Ingevity price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDW

CDW

$86.23

1.31 (1.54%)

06:10
07/18/18
07/18
06:10
07/18/18
06:10
Upgrade
CDW rating change  »

CDW upgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$11.87

-0.275 (-2.27%)

06:10
07/18/18
07/18
06:10
07/18/18
06:10
Periodicals
Former Deutsche Bank exec denies index rigging in Paschi case, Bloomberg says »

Former Deutsche Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTXB

LegacyTexas Financial

$39.01

-0.04 (-0.10%)

06:10
07/18/18
07/18
06:10
07/18/18
06:10
Upgrade
LegacyTexas Financial rating change  »

LegacyTexas upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Sep

MLNX

Mellanox

$84.85

0.9 (1.07%)

06:10
07/18/18
07/18
06:10
07/18/18
06:10
Recommendations
Mellanox analyst commentary  »

Mellanox price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$356.95

0.94 (0.26%)

06:09
07/18/18
07/18
06:09
07/18/18
06:09
Hot Stocks
Boeing announces agreements with ANTONOV, IWG and Cargolux »

Boeing, through its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

CPWR

Compuware

$0.00

(0.00%)

06:08
07/18/18
07/18
06:08
07/18/18
06:08
Hot Stocks
Compuware acquires XaTester and partners with Parasoft »

Compuware announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$25.39

-0.31 (-1.21%)

06:06
07/18/18
07/18
06:06
07/18/18
06:06
Upgrade
Sunoco rating change  »

Sunoco upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$91.84

1.15 (1.27%)

06:06
07/18/18
07/18
06:06
07/18/18
06:06
Upgrade
Comerica rating change  »

Comerica upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$77.25

0.045 (0.06%)

06:05
07/18/18
07/18
06:05
07/18/18
06:05
Hot Stocks
Target says one-day sale generates biggest online shopping day of 2018 »

Hot offers drove the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPLX

MPLX

$33.52

-0.25 (-0.74%)

06:04
07/18/18
07/18
06:04
07/18/18
06:04
Upgrade
MPLX rating change  »

MPLX upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

WMB

Williams

$26.97

-0.28 (-1.03%)

, OKE

Oneok

$70.30

0.29 (0.41%)

06:03
07/18/18
07/18
06:03
07/18/18
06:03
Recommendations
Williams, Oneok analyst commentary  »

Jefferies replaces Oneok…

WMB

Williams

$26.97

-0.28 (-1.03%)

OKE

Oneok

$70.30

0.29 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

GEMP

Gemphire Therapeutics

$7.78

0.525 (7.24%)

06:03
07/18/18
07/18
06:03
07/18/18
06:03
Conference/Events
Gemphire Therapeutics management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

OKE

Oneok

$70.30

0.29 (0.41%)

06:01
07/18/18
07/18
06:01
07/18/18
06:01
Downgrade
Oneok rating change  »

Oneok downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

AMD

AMD

$16.87

0.29 (1.75%)

, NVDA

Nvidia

$253.69

5.48 (2.21%)

06:00
07/18/18
07/18
06:00
07/18/18
06:00
Periodicals
AMD, NVDIA, consortium announce VirtualLink USB-C alt mode, AnandTech says »

A consortium backed by…

AMD

AMD

$16.87

0.29 (1.75%)

NVDA

Nvidia

$253.69

5.48 (2.21%)

MSFT

Microsoft

$106.00

1.09 (1.04%)

FB

Facebook

$209.99

2.66 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 25

    Jul

  • 25

    Jul

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 04

    Sep

  • 18

    Sep

FHN

First Horizon

$17.18

-0.715 (-4.00%)

05:59
07/18/18
07/18
05:59
07/18/18
05:59
Downgrade
First Horizon rating change  »

First Horizon downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPI

Farmland Partners

$6.28

0.185 (3.04%)

05:59
07/18/18
07/18
05:59
07/18/18
05:59
Upgrade
Farmland Partners rating change  »

Farmland Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMP

Magellan Midstream

$67.45

-0.31 (-0.46%)

05:59
07/18/18
07/18
05:59
07/18/18
05:59
Downgrade
Magellan Midstream rating change  »

Magellan Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

IRWD

Ironwood

$21.08

0.27 (1.30%)

05:58
07/18/18
07/18
05:58
07/18/18
05:58
Downgrade
Ironwood rating change  »

Ironwood downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMO

Bank of Montreal

$78.54

-0.26 (-0.33%)

05:58
07/18/18
07/18
05:58
07/18/18
05:58
Upgrade
Bank of Montreal rating change  »

Bank of Montreal upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.42

1.04 (0.37%)

05:57
07/18/18
07/18
05:57
07/18/18
05:57
General news
Trump says 'big results will come' from meeting with Putin »

President Donald Trump…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.42

1.04 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.